Cargando…

329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma

BACKGROUND: Kaposi’s sarcoma (KS) is an AIDS-related condition that is mediated by HHV-8. Although incidence and mortality of KS in the United States have decreased over time since the advent of HAART, there may be disparities in mortality based on geographic location and race/ethnicity, particularl...

Descripción completa

Detalles Bibliográficos
Autores principales: Knights, Sheena, Lazarte, Susana, Kainthla, Radhika, Krieger, Demi, Bhattatiry, Mitu, Chiao, Elizabeth, Nijhawan, Ank E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810747/
http://dx.doi.org/10.1093/ofid/ofz360.402
_version_ 1783462319566618624
author Knights, Sheena
Lazarte, Susana
Kainthla, Radhika
Krieger, Demi
Bhattatiry, Mitu
Chiao, Elizabeth
Nijhawan, Ank E
Nijhawan, Ank E
author_facet Knights, Sheena
Lazarte, Susana
Kainthla, Radhika
Krieger, Demi
Bhattatiry, Mitu
Chiao, Elizabeth
Nijhawan, Ank E
Nijhawan, Ank E
author_sort Knights, Sheena
collection PubMed
description BACKGROUND: Kaposi’s sarcoma (KS) is an AIDS-related condition that is mediated by HHV-8. Although incidence and mortality of KS in the United States have decreased over time since the advent of HAART, there may be disparities in mortality based on geographic location and race/ethnicity, particularly African-American men in the South. METHODS: A retrospective electronic medical record review was conducted using integrated inpatient and outpatient data in EPIC from PHHS. We included all individuals with a diagnosis of HIV and Kaposi’s sarcoma between January 1, 2009 and December 31, 2018 based on ICD-9/10 codes. We collected demographic information, HIV history, variables related to HIV and KS diagnosis, treatment and outcomes data for each patient. We calculated hazard ratios using Cox proportional hazards modeling. RESULTS: We identified 252 patients with KS. 95% of patients were male, and the majority were MSM (men who have sex with men; 77% of all patients). 35% of patients were Hispanic, 34% were African-American and 31% were Caucasian. Over half (56%) of patients were funded through Ryan White or were uninsured. The median CD4 count and viral load at the time of cancer diagnosis were 44 and 73,450, respectively. 24% of patients were confirmed to have died by the end of the study time frame. However, due to loss to follow-up, 35% of the cohort had an unknown vital status at the time of the final chart review. Variables most strongly associated with mortality were >2 hospitalizations in the first 6 months of cancer diagnosis (aHR=4.93, P = 0.0003), IV drug use (aHR=3.61, P = 0.0009), and T1 stage of KS (aHR= 2.13, P = 0.0264). African American patients had lower survival than Caucasian or Hispanic patients, with a 5-year survival of 69%, 81% and 80% respectively, although this did not reach statistical significance (aHR 1.77, P = 0.1396). CONCLUSION: We describe a large cohort of patients with HIV and HHV-8-related disease, who are predominantly of minority race/ethnicity, uninsured, and have advanced HIV disease. Factors associated with mortality include Black/African-American ethnicity, number of hospitalizations, IV drug use and T1 stage of KS. Our mortality analysis is limited due to high lost to follow-up rates, so we suspect overall mortality in our cohort is higher than currently reported. [Image: see text] DISCLOSURES: Ank E. Nijhawan, MD, MPH, Gilead Sciences, Inc.: Research Grant.
format Online
Article
Text
id pubmed-6810747
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68107472019-10-28 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma Knights, Sheena Lazarte, Susana Kainthla, Radhika Krieger, Demi Bhattatiry, Mitu Chiao, Elizabeth Nijhawan, Ank E Nijhawan, Ank E Open Forum Infect Dis Abstracts BACKGROUND: Kaposi’s sarcoma (KS) is an AIDS-related condition that is mediated by HHV-8. Although incidence and mortality of KS in the United States have decreased over time since the advent of HAART, there may be disparities in mortality based on geographic location and race/ethnicity, particularly African-American men in the South. METHODS: A retrospective electronic medical record review was conducted using integrated inpatient and outpatient data in EPIC from PHHS. We included all individuals with a diagnosis of HIV and Kaposi’s sarcoma between January 1, 2009 and December 31, 2018 based on ICD-9/10 codes. We collected demographic information, HIV history, variables related to HIV and KS diagnosis, treatment and outcomes data for each patient. We calculated hazard ratios using Cox proportional hazards modeling. RESULTS: We identified 252 patients with KS. 95% of patients were male, and the majority were MSM (men who have sex with men; 77% of all patients). 35% of patients were Hispanic, 34% were African-American and 31% were Caucasian. Over half (56%) of patients were funded through Ryan White or were uninsured. The median CD4 count and viral load at the time of cancer diagnosis were 44 and 73,450, respectively. 24% of patients were confirmed to have died by the end of the study time frame. However, due to loss to follow-up, 35% of the cohort had an unknown vital status at the time of the final chart review. Variables most strongly associated with mortality were >2 hospitalizations in the first 6 months of cancer diagnosis (aHR=4.93, P = 0.0003), IV drug use (aHR=3.61, P = 0.0009), and T1 stage of KS (aHR= 2.13, P = 0.0264). African American patients had lower survival than Caucasian or Hispanic patients, with a 5-year survival of 69%, 81% and 80% respectively, although this did not reach statistical significance (aHR 1.77, P = 0.1396). CONCLUSION: We describe a large cohort of patients with HIV and HHV-8-related disease, who are predominantly of minority race/ethnicity, uninsured, and have advanced HIV disease. Factors associated with mortality include Black/African-American ethnicity, number of hospitalizations, IV drug use and T1 stage of KS. Our mortality analysis is limited due to high lost to follow-up rates, so we suspect overall mortality in our cohort is higher than currently reported. [Image: see text] DISCLOSURES: Ank E. Nijhawan, MD, MPH, Gilead Sciences, Inc.: Research Grant. Oxford University Press 2019-10-23 /pmc/articles/PMC6810747/ http://dx.doi.org/10.1093/ofid/ofz360.402 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Knights, Sheena
Lazarte, Susana
Kainthla, Radhika
Krieger, Demi
Bhattatiry, Mitu
Chiao, Elizabeth
Nijhawan, Ank E
Nijhawan, Ank E
329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma
title 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma
title_full 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma
title_fullStr 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma
title_full_unstemmed 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma
title_short 329. Health Disparities Among HIV-Positive Patients with Kaposi’s Sarcoma
title_sort 329. health disparities among hiv-positive patients with kaposi’s sarcoma
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810747/
http://dx.doi.org/10.1093/ofid/ofz360.402
work_keys_str_mv AT knightssheena 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma
AT lazartesusana 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma
AT kainthlaradhika 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma
AT kriegerdemi 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma
AT bhattatirymitu 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma
AT chiaoelizabeth 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma
AT nijhawananke 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma
AT nijhawananke 329healthdisparitiesamonghivpositivepatientswithkaposissarcoma